An Adjunctive Use Of Asfotase Alfa and Zoledronic Acid After Spinal Surgery In Neurofibromatosis Type 1 Related Dystrophic Scoliosis
Open Access
- 1 November 2020
- journal article
- Published by Elsevier BV in AACE Clinical Case Reports
- Vol. 6 (6), e305-e310
- https://doi.org/10.4158/accr-2020-0222
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Predictive Value and Interrater Reliability of Radiographic Factors in Neurofibromatosis Patients With Dystrophic ScoliosisSpine Deformity, 2018
- Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1Nature Medicine, 2014
- Orthopaedic aspects of neurofibromatosis: updateCurrent Opinion in Pediatrics, 2011
- Orthopaedic Manifestations of Neurofibromatosis Type 1Journal of the American Academy of Orthopaedic Surgeons, 2010
- High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1Osteoporosis International, 2009
- Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1–haploinsufficient osteoclast functionsJCI Insight, 2006
- Pathophysiology of Neurofibromatosis Type 1Annals of Internal Medicine, 2006
- Decreased bone mineral density in patients with neurofibromatosis 1Osteoporosis International, 2005
- Modulation of Spinal Deformities in Patients With Neurofibromatosis Type 1Spine, 2000
- The Diagnostic Evaluation and Multidisciplinary Management of Neurofibromatosis 1 and Neurofibromatosis 2JAMA, 1997